Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT) 2A and 5-HT2C receptors
This comparative study on 2,5-Dimethoxy-4-substituted phenylisopropylamines and phenethylamines examines their activity as serotonin 5-HT2A/2C agonists. It finds that phenylisopropylamines generally exhibit higher efficacy than phenethylamines at the 5-HT2A receptor, but both act as partial agonists at the 5-HT2C receptor. The research highlights differential activation of phospholipase C (PLC) and phospholipase A2 (PLA2) pathways by these compounds in cell-based assays, with phenylisopropylamines showing stronger efficacy as head shake inducers in rats, supporting the concept of functional selectivity in receptor signaling pathways.
Authors
- Moya, P. R.
- Berg, K. A.
- Gutiérrez-Hernandez, M. A.
Published
Abstract
2,5-Dimethoxy-4-substituted phenylisopropylamines and phenethylamines are 5-hydroxytryptamine (serotonin) (5-HT)2A/2C agonists. The former are partial to full agonists, whereas the latter are partial to weak agonists. However, most data come from studies analyzing phospholipase C (PLC)-mediated responses, although additional effectors [e.g., phospholipase A2 (PLA2)] are associated with these receptors. We compared two homologous series of phenylisopropylamines and phenethylamines measuring both PLA2 and PLC responses in Chinese hamster ovary-K1 cells expressing human 5-HT2A or 5-HT2C receptors. In addition, we assayed both groups of compounds as head shake inducers in rats. At the 5-HT2C receptor, most compounds were partial agonists for both pathways. Relative efficacy of some phenylisopropylamines was higher for both responses compared with their phenethylamine counterparts, whereas for others, no differences were found. At the 5-HT2A receptor, most compounds behaved as partial agonists, but unlike findings at 5-HT2C receptors, all phenylisopropylamines were more efficacious than their phenethylamine counterparts. 2,5-Dimethoxyphenylisopropylamine activated only the PLC pathway at both receptor subtypes, 2,5-dimethoxyphenethylamine was selective for PLC at the 5-HT2C receptor, and 2,5-dimethoxy-4-nitrophenethylamine was PLA2-specific at the 5-HT2A receptor. For both receptors, the rank order of efficacy of compounds differed depending upon which response was measured. The phenylisopropylamines were strong head shake inducers, whereas their phenethylamine congeners were not, in agreement with in vitro results and the involvement of 5-HT2A receptors in the head shake response. Our results support the concept of functional selectivity and indicate that subtle changes in ligand structure can result in significant differences in the cellular signaling profile.
Research Summary of 'Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT) 2A and 5-HT2C receptors'
Blossom's Take
We are only tracking a handful of studies that measure 2C-B (-like) compounds, and this study provides a very detailed account of how both influence cells as well as the behaviour in rats.
Introduction
Earlier research has established that 2,5-dimethoxy-4-substituted phenylisopropylamines (α‑methylated hallucinogenic amphetamine derivatives such as DOI, DOM, DOB) and their α‑demethylated phenethylamine counterparts (e.g., 2C‑I, 2C‑B, 2C‑D) act as agonists at human 5‑hydroxytryptamine (5‑HT) 2A and 5‑HT2C G protein‑coupled receptors. Most prior in vitro work focused on one downstream pathway, phospholipase C (PLC)–mediated inositol phosphate (IP) accumulation, despite evidence that these receptors also couple to additional effectors such as phospholipase A2 (PLA2)–mediated arachidonic acid (AA) release. Classical receptor theory assumed intrinsic efficacy to be a ligand constant independent of the effector pathway, but accumulating data across receptor families have undermined that view and motivated the concept of agonist‑directed trafficking or functional selectivity, whereby ligands stabilise distinct receptor conformations that preferentially engage particular signalling cascades. Moya and colleagues set out to test functional selectivity within two homologous series of hallucinogenic ligands by measuring both PLC and PLA2 responses in the same cell system expressing human 5‑HT2A or 5‑HT2C receptors. They compared relative efficacies and potencies of several phenylisopropylamines and their phenethylamine congeners across the two pathways, and they also examined whether in vitro differences at 5‑HT2A receptors corresponded with an established in vivo index of 5‑HT2A activation, the head‑shake behaviour in rats. The goal was to determine whether subtle structural changes, such as α‑methylation or different 4‑position substituents, produce pathway‑selective signalling profiles.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- APA Citation
Moya, P. R., Berg, K. A., Gutiérrez-Hernandez, M. A., Sáez-Briones, P., Reyes-Parada, M., Cassels, B. K., & Clarke, W. P. (2007). Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT) 2A and 5-HT2C receptors. The Journal of Pharmacology and Experimental Therapeutics, 321(3), 1054-1061. https://doi.org/10.1124/jpet.106.117507
Cited By (11)
Papers in Blossom that reference this study
Wallach, J., Cao, A. B., Calkins, M. M. et al. · Biorxiv (2023)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Souza, D. C. D., Pérez, C., Papaseit, E. et al. · Frontiers in Pharmacology (2018)
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nau, F., Miller, J., Saravia, J. et al. · American Journal of Physiology (2015)
Halberstadt, A. L. · Behavioural Brain Research (2014)
Show all 11 papersShow fewer
Páleníček, T., Fujáková, M., Brunovský, M. et al. · Psychopharmacology (2012)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.